Lupin, Zydus file US antitrust counterclaims in Astellas patent case over Myrbetriq
MLex Summary: Lupin and Zydus Pharmaceuticals filed counterclaims in Astellas' patent case, accusing it of maintaining a monopoly over the market for the active ingredient of Myrbetriq by manipulating the patent process...To view the full article, register now.
Already a subscriber? Click here to view full article